Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, ...

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

INNOVATE Corp. surged 150% after its subsidiary MediBeacon received FDA approval for its TGFR system. See why I rate VATE ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A post hoc analysis of trial data published in Diabetes Care found that adults with type 2 diabetes receiving tirzepatide ...

In a remarkable display of market confidence, VATE stock has surged to a 52-week high, with shares trading at an impressive $13.31, representing a dramatic 309% increase from its 52-week low of $3.25.

This model exhibits ... New Method Predicts Worsening of Chronic Kidney Disease Sep. 12, 2024 — Researchers have developed a new method that could be a significant step in the treatment of ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.